MedTrace Logo

Thymosin-α1 for Recurrent Implantation Failure

NCT07675980 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-06-30

No results posted yet for this study

Summary

Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.

Conditions

  • Recurrent Implantation Faliure

Interventions

DRUG

Thymosin Alpha1

Start at luteal start in ART cycles and continue until 10+6 weeks' gestation.

OTHER

Placebo Control

Matching placebo injections on the same schedule and duration.

Sponsors & Collaborators

  • Fakih IVF Fertility Center

    lead OTHER

Principal Investigators

  • Michael Fakih, MD · Fakih IVF Abu Dhabi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-11
Primary Completion
2027-02-28
Completion
2027-06-30

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07675980 on ClinicalTrials.gov